193 related articles for article (PubMed ID: 19646547)
21. Vascular endothelial growth factor and vascular permeability changes in human diabetic retinopathy.
Mathews MK; Merges C; McLeod DS; Lutty GA
Invest Ophthalmol Vis Sci; 1997 Dec; 38(13):2729-41. PubMed ID: 9418725
[TBL] [Abstract][Full Text] [Related]
22. Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab.
Ma Y; Zhang Y; Zhao T; Jiang YR
Am J Ophthalmol; 2012 Feb; 153(2):307-313.e2. PubMed ID: 21982107
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic anti-VEGF antibodies.
Lien S; Lowman HB
Handb Exp Pharmacol; 2008; (181):131-50. PubMed ID: 18071944
[TBL] [Abstract][Full Text] [Related]
24. Update on nonsurgical therapy for diabetic macular edema.
Witkin AJ; Brown GC
Curr Opin Ophthalmol; 2011 May; 22(3):185-9. PubMed ID: 21427573
[TBL] [Abstract][Full Text] [Related]
25. Effects of TNF-α inhibitors upon the mechanisms of action of VEGF.
Murdaca G; Spanò F; Miglino M; Puppo F
Immunotherapy; 2013 Feb; 5(2):113-5. PubMed ID: 23413901
[No Abstract] [Full Text] [Related]
26. [VEGF, anti-vEGF and diseases].
Corvol P
Bull Acad Natl Med; 2008 Feb; 192(2):289-300; discussion 300-2. PubMed ID: 18819684
[TBL] [Abstract][Full Text] [Related]
27. Pharmacologic therapy for diabetic retinopathy.
Gardlik R; Fusekova I
Semin Ophthalmol; 2015 Jul; 30(4):252-63. PubMed ID: 24571780
[TBL] [Abstract][Full Text] [Related]
28. Succinate increases in the vitreous fluid of patients with active proliferative diabetic retinopathy.
Matsumoto M; Suzuma K; Maki T; Kinoshita H; Tsuiki E; Fujikawa A; Kitaoka T
Am J Ophthalmol; 2012 May; 153(5):896-902.e1. PubMed ID: 22265145
[TBL] [Abstract][Full Text] [Related]
29. Growth factors and diabetic retinopathy.
Paques M; Massin P; Gaudric A
Diabetes Metab; 1997 Apr; 23(2):125-30. PubMed ID: 9137900
[TBL] [Abstract][Full Text] [Related]
30. Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy.
Zhang SX; Wang JJ; Gao G; Parke K; Ma JX
J Mol Endocrinol; 2006 Aug; 37(1):1-12. PubMed ID: 16901919
[TBL] [Abstract][Full Text] [Related]
31. Role of soluble vascular endothelial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy.
Matsunaga N; Chikaraishi Y; Izuta H; Ogata N; Shimazawa M; Matsumura M; Hara H
Ophthalmology; 2008 Nov; 115(11):1916-22. PubMed ID: 18718666
[TBL] [Abstract][Full Text] [Related]
32. Vascular endothelial growth factor in diabetes induced early retinal abnormalities.
Cukiernik M; Hileeto D; Evans T; Mukherjee S; Downey D; Chakrabarti S
Diabetes Res Clin Pract; 2004 Sep; 65(3):197-208. PubMed ID: 15331199
[TBL] [Abstract][Full Text] [Related]
33. Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy.
Qian J; Lu Q; Tao Y; Jiang YR
Retina; 2011 Jan; 31(1):161-8. PubMed ID: 20890241
[TBL] [Abstract][Full Text] [Related]
34. Effects of ischemic preconditioning and bevacizumab on apoptosis and vascular permeability following retinal ischemia-reperfusion injury.
Abcouwer SF; Lin CM; Wolpert EB; Shanmugam S; Schaefer EW; Freeman WM; Barber AJ; Antonetti DA
Invest Ophthalmol Vis Sci; 2010 Nov; 51(11):5920-33. PubMed ID: 20554620
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic potential of a monoclonal antibody blocking the Wnt pathway in diabetic retinopathy.
Lee K; Hu Y; Ding L; Chen Y; Takahashi Y; Mott R; Ma JX
Diabetes; 2012 Nov; 61(11):2948-57. PubMed ID: 22891217
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of vascular endothelial growth factor (VEGF) is sufficient to completely restore barrier malfunction induced by growth factors in microvascular retinal endothelial cells.
Deissler HL; Deissler H; Lang GE
Br J Ophthalmol; 2011 Aug; 95(8):1151-6. PubMed ID: 21273213
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of troxerutin on streptozotocin-induced rat model in the early stage of diabetic retinopathy.
Chung HK; Choi SM; Ahn BO; Kwak HH; Kim JH; Kim WB
Arzneimittelforschung; 2005; 55(10):573-80. PubMed ID: 16294503
[TBL] [Abstract][Full Text] [Related]
38. Regression of iris neovascularisation secondary to diabetic retinopathy with subconjunctival anti-VEGF therapy.
Rao RC; Choudhry N; Apte RS
Lancet Diabetes Endocrinol; 2014 Feb; 2(2):182. PubMed ID: 24622722
[No Abstract] [Full Text] [Related]
39. Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress.
Caldwell RB; Bartoli M; Behzadian MA; El-Remessy AE; Al-Shabrawey M; Platt DH; Liou GI; Caldwell RW
Curr Drug Targets; 2005 Jun; 6(4):511-24. PubMed ID: 16026270
[TBL] [Abstract][Full Text] [Related]
40. Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy.
LeBlanc ME; Wang W; Chen X; Caberoy NB; Guo F; Shen C; Ji Y; Tian H; Wang H; Chen R; Li W
J Exp Med; 2017 Apr; 214(4):1029-1047. PubMed ID: 28330905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
